Overview

Metformin in Safety and Efficacy in Gouty Patients

Status:
RECRUITING
Trial end date:
2026-11-20
Target enrollment:
Participant gender:
Summary
The most frequent crystal arthropathy is gout, which is also the most prevalent cause of inflammatory arthritis. Gouty Patients frequently have excruciating pain and swelling in their joints. Gout is linked to decreased health-related quality of life and functional disability. Gout and its associated diseases have been shown to have a significant impact on patients mortality and morbidities. Metformin, a biguanide, is used to manage diabetes by reducing insulin resistance and preventing comorbidities such as cerebrovascular and coronary artery disease, as well as providing renal protection to diabetic nephropathy patients
Phase:
PHASE2
Details
Lead Sponsor:
Mostafa Bahaa
Treatments:
Metformin